Latest Earnings Results: Q3 '26
Estimated EPS
-$0.24
Reported EPS
-$1.02
Surprise
-322.07%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
• Reported GAAP EPS of -$0.20 up 54.55% YoY • Nuvectis Pharma expects research and development expenses to increase substantially in the near term and beyond, and general and administrative expenses to increase in the future as headcount expands to support development and corporate activities.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.37 | -- | -- | N/A |
Q3 '26 | -$0.24 | -$1.02 | -322.07% | MISSED |
Q2 '26 | -$0.26 | -$0.30 | -14.50% | MISSED |
Q1 '26 | -$0.31 | -$0.26 | 17.20% | BEAT |
Q4 '25 | -$0.32 | -$0.31 | 1.90% | BEAT |